Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Gustave Roussy joins the Worldwide Innovative Network (WIN) in personalized cancer medicine consortium- WIN Consortium
On
29 april 2021
Gustave Roussy joins the Worldwide Innovative Network (WIN) in personalized cancer medicine consortium- WIN Consortium
Gustave Roussy and Worldwide Innovative Networking (WIN) in personalized cancer medicine consortium join forces to advance innovative cancer research.
"By joining the global network of WIN, Gustave Roussy is expecting to increase its global impact and to help improve cancer outcomes across the world," said Prof. Jean-Charles Soria, General Director of Gustave Roussy.
“We are very proud to welcome Gustave Roussy back to WIN,” said Dr. Richard L Schilsky, Chairman of WIN, and past ASCO Executive Vice President and Chief Medical Officer (2013-2021), “Gustave Roussy is a leader among European cancer research centers with remarkable research, talented faculty and innovative leadership and will be a major asset for WIN. As a founding member of WIN, Gustave Roussy contributed to the vision and facilitated the launch of a global precision cancer medicine consortium that has come to fruition in WIN. We are delighted that they are returning to the Consortium at a pivotal time in its history.”
WIN’s strategy to significantly improve survival and quality of life of patients is to perform innovative trials that explore novel strategies and tools to increase the efficacy of Precision Oncology for advanced cancers and improve early diagnosis. "WIN has developed a unique biomarker platform based on both genomics and transcriptomics, already demonstrated to significantly increasing the number of patients gaining access to targeted and immuno therapies," said Dr. Josep Tabernero, Vice-Chairman and Chairman of Scientific Advisory Board of WIN, Director, Vall d'Hebron Institute of Oncology, VHIO (Spain) and past ESMO President (2018-2019).
"WIN's unique approach to matching the right patient with the right drug was first tested in the innovative WINTHER trial led by Gustave Roussy. We are looking forward to resuming the fruitful participation in WIN and to bringing our institutional expertise to the global community through the consortium," concluded Prof. Jean-Charles Soria.
About WIN Consortium
WIN Consortium is a non-profit association headquartered in France. The WIN network assembles 35 world-class academic medical centers, industries (pharmaceutical and diagnostic companies), research organizations and patient advocates spanning 19 countries and 4 continents, aligned to launch trials using its genomics and transcriptomics biomarker platform to bolster Precision Oncology across the world. WIN is the organizer of the WIN symposia in Precision Oncology.
Contact
www.winconsortium.org
www.winsymposium.org
Vladimir Lazar
Tel: +33 66 109 1522
Chief Scientific and Operating Officer
vladimir.lazar@winconsortium.org
Press contact
If you are a journalist and have a question, please contact:
Claire Parisel or Léona Pinto
Tel. +33 1 42 11 50 59
Tel. +33 1 42 11 63 59
Mob. +33 6 17 66 00 26
Email
The Media Team cannot respond to patient inquiries.
Last press releases
-
Gold september: two new research programmes launched to tackle childhood cancers
Two of Gustave Roussy’s four new medical and scientific programmes are dedicated to childhood cancers. The first, DECRIPT, aims to improve understanding of the role played by genetics in the development of certain childhood cancers, as well as second cancers that may occur in adulthood. The second, INSPIRE, will draw on the knowledge and techniques already developed at the Institute to create organoids, with the aim of deciphering the mechanisms underlying metastasis and resistance to treatment.
-
Prof. Fabrice Barlesi reappointed at the head of Gustave Roussy, the leading cancer center in France and Europe
By order of Ms. Stéphanie Rist, Minister of Health, Families, Autonomy and Persons with Disabilities, dated 27 July 2026, Professor Fabrice Barlesi has been reappointed as Director General of Gustave Roussy, effective 1 August 2026. At the helm of the Institute for five more years, Prof. Barlesi will continue the transformations undertaken during his first term. This renewal reflects the confidence placed in the project led by the institution to accelerate progress in the fight against cancer, foster and support the development of innovations set to change the future of oncology, and strengthen the influence of one of the world's leading cancer centers.
-
Route du Rhum 2026 Jean Le Cam and Christophe Rateau to sail for Gustave Roussy
For the Route du Rhum - Destination Guadeloupe 2026, Jean Le Cam and Christophe Rateau will sail under the colors of Gustave Roussy, the leading cancer center in France and Europe. Competing respectively in the Vintage and Class40 categories, the two skippers will carry the Institute's mission to the general public, supporting cancer research and raising awareness of prevention, innovation and patient care.
-
Owkin and Gustave Roussy partner to bring K Pro into real-world clinical practice
Owkin and Gustave Roussy, Europe's leading cancer center, today announced a partnership to test K Pro directly within the hospital's real-world clinical and research workflows.
